A Phase II Study of Eribulin and Pembrolizumab in Soft Tissue Sarcomas
Latest Information Update: 06 Dec 2024
At a glance
- Drugs Eribulin (Primary) ; Pembrolizumab (Primary)
- Indications Leiomyosarcoma; Liposarcoma; Malignant fibrous histiocytoma; Sarcoma; Soft tissue sarcoma
- Focus Therapeutic Use
Most Recent Events
- 03 Dec 2024 Planned End Date changed from 1 Aug 2025 to 16 Jul 2025.
- 14 May 2024 Planned End Date changed from 1 Aug 2024 to 1 Aug 2025.
- 14 May 2024 Planned primary completion date changed from 1 Aug 2024 to 1 Aug 2025.